Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 6.5% in that time frame, outperforming the S&P 500. But investors have to be ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

I’ve been able to spot AI-generated content for over a decade. And now that ChatGPT has been so widespread for so long, almost everyone else can spot it too. Especially if it contains a few ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...

Costco’s stock remained steady, closing at $914.80 with no percentage change. The stock reached an intraday high of $916.38 and a low of $910.96, while its 52-week high and low are $1078.23 and ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...